Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Royal Bank Of Canada in a research report issued on Monday,Benzinga reports. They currently have a $100.00 price target on the biotechnology company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 17.77% from the company’s current price.
Several other equities analysts have also commented on the stock. Leerink Partners upped their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research report on Wednesday, June 17th. JPMorgan Chase & Co. boosted their target price on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Morgan Stanley upped their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Sanford C. Bernstein raised their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $115.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $98.42.
Check Out Our Latest Report on Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Stock Performance
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.Arrowhead Pharmaceuticals’s quarterly revenue was up 171.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.26) earnings per share. Equities research analysts expect that Arrowhead Pharmaceuticals will post -3.51 EPS for the current year.
Insider Activity
In other news, Director Michael S. Perry sold 11,600 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the sale, the director directly owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the transaction, the director owned 31,600 shares of the company’s stock, valued at $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.60% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Arrowhead Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tsfg LLC bought a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at $25,000. Optiver Holding B.V. raised its stake in shares of Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after buying an additional 186 shares in the last quarter. Versant Capital Management Inc raised its stake in shares of Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after buying an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 154 shares during the period. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at $29,000. Institutional investors own 62.61% of the company’s stock.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company’s pipeline includes multiple candidates in various stages of development.
Read More
- Five stocks we like better than Arrowhead Pharmaceuticals
- Broadcom’s Earnings Test Comes With a Higher Bar After NVIDIA’s Blowout
- Palo Alto’s Rally Has One Big Problem Ahead of Earnings
- These 5 ETFs Have Raked in Cash This Year—What Do They All Have in Common?
- DLocal Is Testing the Breakout Level That Could Change Its Stock Story
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
